Merck KGaA Profit Beats Estimates on Cost-Cutting

May 14 (Bloomberg) -- Merck KGaA, the German maker of cancer drug Erbitux, said first-quarter profit rose on higher-than-expected savings from a reorganization program, and forecast it will achieve 2014 targets a year ahead of schedule. Mark Barton reports on Bloomberg Television's "Countdown." (Source: Bloomberg)
Singapore's New Normal: ANZ Makes Case for Low Growth
50:31 - Weiwen Ng, an economist at Australia & New Zealand Banking Group Ltd., talks about Singapore's economy and central bank policy after the nation narrowly avoided a technical recession. Ng speaks with Angie Lau on Bloomberg Television's "First Up." (Source: Bloomberg)
  • Weaker Yuan: Why RBC's Tenengauzer Sees Declines in 2016
  • The Top Three Stocks to Watch in Asia Today
  • JPMorgan Earnings: What'd You Miss? (Full Show 10/13)